S
Shanghai Ruining Biotechnology
Medical hydrogel products for oncology and intervention
About Shanghai Ruining Biotechnology
Shanghai Ruining Biotechnology Co., Ltd. (Reunion Biotech) is a high-tech enterprise focused on the research, development, and commercialization of high-end biomedical materials. The company was founded by PhDs who returned from overseas and is dedicated to bringing advanced biomaterials to market. Reunion Biotech has developed a leading medical hydrogel technology platform to create medical device solutions for oncology. A key feature is its proprietary "ready-to-use" polyethylene glycol (PEG) hydrogel platform.
The company's product pipeline includes innovative Class III medical devices designed for minimally invasive treatments through implantation and intervention. These solutions address clinical needs such as tumor radiotherapy protection, wound repair, and tumor embolization. For instance, its Radiotherapy Hydrogel Spacer is a solution-stable, "ready-to-use" formulation. In early 2026, the company's tumor "Embolization Hydrogel" was accepted into the National Innovative Medical Device "Green Channel," a significant milestone.
Reunion Biotech operates from a facility of over 4,000 square meters, which includes a Research & Development center, GMP (Good Manufacturing Practice) facilities, and laboratories for physical, chemical, and microbiological testing. The company has secured hundreds of millions of RMB in investment from notable venture capital firms, including Qiming Venture Capital. It collaborates with universities, research institutes, and top-tier hospitals to drive product innovation. In recognition of its intellectual property management and commercialization capabilities, the Shanghai Intellectual Property Bureau named Reunion Bio a “Shanghai Patent Work Demonstration Enterprise” for 2025.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.3/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Oncology, medical implants, Surgery, Advanced Materials, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Feb 2026 | $14M | $55M | Qiming Venture Partners | ↗ |
| SERIES B✓Equity / VC | Jan 2024 | $14M | $55M | Dingxin Capital | ↗ |
Growth signals
Latest recorded traffic for Shanghai Ruining Biotechnology is 160 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Ruining Biotechnology in its local ecosystem
The Shanghai Ruining Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Qiming Venture Partners- DCDingxin Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Ruining Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Ruining Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










